Search

Your search keyword '"Morgades, M"' showing total 2 results
Start Over Author "Morgades, M" Publisher escholarship, university of california
2 results on '"Morgades, M"'

1. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Author

Gökbuget, N, Kelsh, M, Chia, V, Advani, A, Bassan, R, Dombret, H, Doubek, M, Fielding, AK, Giebel, S, Haddad, V, Hoelzer, D, Holland, C, Ifrah, N, Katz, A, Maniar, T, Martinelli, G, Morgades, M, O'Brien, S, Ribera, J-M, Rowe, JM, Stein, A, Topp, M, Wadleigh, M, and Kantarjian, H

Subjects
Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis
Abstract

We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. Estimates of complete remission (CR) and overall survival (OS) were weighted by the frequency distribution of prognostic factors in the blinatumomab trial. Outcomes were also compared between the trial and historical data using propensity score methods. The historical cohort included 694 patients with CR data and 1112 patients with OS data compared with 189 patients with CR and survival data in the blinatumomab trial. The weighted analysis revealed a CR rate of 24% (95% CI: 20-27%) and a median OS of 3.3 months (95% CI: 2.8-3.6) in the historical cohort compared with a CR/CRh rate of 43% (95% CI: 36-50%) and a median OS of 6.1 months (95% CI: 4.2-7.5) in the blinatumomab trial. Propensity score analysis estimated increased odds of CR/CRh (OR=2.68, 95% CI: 1.67-4.31) and improved OS (HR=0.536, 95% CI: 0.394-0.730) with blinatumomab. The analysis demonstrates the application of different study designs and statistical methods to compare novel therapies for R/R ALL with historical data.

Published
2016

2. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Author

Renato Bassan, Chris Holland, Chia, Hagop M. Kantarjian, Mireia Morgades, Haddad, Dieter Hoelzer, Anthony S. Stein, Martha Wadleigh, Michael Doubek, Nicola Gökbuget, Sebastian Giebel, Josep-Maria Ribera, Aaron J. Katz, Hervé Dombret, Max S. Topp, Rowe Jm, Anjali S. Advani, Norbert Ifrah, Tapan Maniar, Susan O'Brien, Michael A. Kelsh, Adele K. Fielding, Giovanni Martinelli, Gökbuget, N, Kelsh, M, Chia, V, Advani, A, Bassan, R, Dombret, H, Doubek, M, Fielding, A K, Giebel, S, Haddad, V, Hoelzer, D, Holland, C, Ifrah, N, Katz, A, Maniar, T, Martinelli, G, Morgades, M, O'Brien, S, Ribera, J-M, Rowe, J M, Stein, A, Topp, M, Wadleigh, M, and Kantarjian, H

Subjects
Oncology, Adult, Pediatrics, medicine.medical_specialty, Comparative Effectiveness Research, Blinatumomab, Pediatric Cancer, Childhood Leukemia, Lymphoblastic Leukemia, education, Oncology and Carcinogenesis, Antineoplastic Agents, Cardiorespiratory Medicine and Haematology, 03 medical and health sciences, 0302 clinical medicine, Rare Diseases, Refractory, hemic and lymphatic diseases, Internal medicine, Antibodies, Bispecific, medicine, Humans, ddc:610, Letter to the Editor, Cancer, Pediatric, Hematology, business.industry, hemic and immune systems, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, humanities, Lymphoma, Leukemia, 030220 oncology & carcinogenesis, Propensity score matching, Relapsed refractory, Immunology, Original Article, business, Standard therapy, Historical Cohort, 030215 immunology, medicine.drug
Abstract

We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. Estimates of complete remission (CR) and overall survival (OS) were weighted by the frequency distribution of prognostic factors in the blinatumomab trial. Outcomes were also compared between the trial and historical data using propensity score methods. The historical cohort included 694 patients with CR data and 1112 patients with OS data compared with 189 patients with CR and survival data in the blinatumomab trial. The weighted analysis revealed a CR rate of 24% (95% CI: 20–27%) and a median OS of 3.3 months (95% CI: 2.8–3.6) in the historical cohort compared with a CR/CRh rate of 43% (95% CI: 36–50%) and a median OS of 6.1 months (95% CI: 4.2–7.5) in the blinatumomab trial. Propensity score analysis estimated increased odds of CR/CRh (OR=2.68, 95% CI: 1.67–4.31) and improved OS (HR=0.536, 95% CI: 0.394–0.730) with blinatumomab. The analysis demonstrates the application of different study designs and statistical methods to compare novel therapies for R/R ALL with historical data.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results